Apr 5 |
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
|
Apr 2 |
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
|
Mar 22 |
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
|
Mar 20 |
Hutchmed Is Turning Profitable
|
Mar 14 |
Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
|
Mar 13 |
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
|
Mar 1 |
HUTCHMED (China) Full Year 2023 Earnings: EPS: US$0.12 (vs US$0.43 loss in FY 2022)
|
Feb 14 |
Airbnb Reports Q4 Results, Joins MGM Resorts, Upstart And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
|
Feb 2 |
Hutchmed grants exclusive license to Inmagene for two drug candidates
|
Feb 2 |
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
|